136.35MXN
19.72 BMXN
159.95 BMXN
144.19 M
About BIOGEN INC
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Employees (FY)
7.57 K
Founded
1978
ISIN
US09062X1037
FIGI
BBG004PYDM88
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BIIB is featured.
Frequently Asked Questions
The current price of BIIB is 3410.11 MXN — it has decreased by 3.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange BIOGEN INC stocks are traded under the ticker BIIB.
BIOGEN INC is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
BIIB stock is 3.31% volatile and has beta coefficient of 0.74. Check out the list of the most volatile stocks — is BIOGEN INC there?
One year price forecast for BIOGEN INC has a max estimate of 6669.95 MXN and a min estimate of 3615.01 MXN.
BIIB earnings for the last quarter are 76.00 MXN whereas the estimation was 69.26 MXN which accounts for 9.73% surprise. Estimated earnings for the next quarter are 54.08 MXN. See more details about BIOGEN INC earnings.
BIOGEN INC revenue for the last quarter amounts to 44.10 B MXN despite the estimated figure of 41.83 B MXN. In the next quarter revenue is expected to reach 41.88 B MXN.
Yes, you can track BIOGEN INC financials in yearly and quarterly reports right on TradingView.
BIIB stock has fallen by 3.20% compared to the previous week, the month change is a 11.43% fall, over the last year BIOGEN INC has showed a 31.87% decrease.
BIIB net income for the last quarter is 4.24 B MXN, while the quarter before that showed −1.19 B MXN of net income which accounts for 457.29% change. Track more BIOGEN INC financial stats to get the full picture.
Today BIOGEN INC has the market capitalization of 472.98 B, it has decreased by 2.66% over the last week.
No, BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 7.57 K employees. See our rating of the largest employees — is BIOGEN INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN INC stock shows the strong sell signal. See more of BIOGEN INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BIOGEN INC future price: according to them, BIIB price has a max estimate of 6669.95 MXN and a min estimate of 3615.01 MXN. Read a more detailed BIOGEN INC forecast: see what analysts think of BIOGEN INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN INC EBITDA is 36.11 B MXN, and current EBITDA margin is 22.58%. See more stats in BIOGEN INC financial statements.